CpG 8954
Latest Information Update: 02 Jul 2023
Price :
$50 *
At a glance
- Originator Coley Pharmaceutical Group
- Class
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Viral infections
Most Recent Events
- 21 Jan 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 21 Jan 2008 Discontinued - Preclinical for Viral infections in USA (unspecified route)
- 26 May 2006 No development reported - Preclinical for Cancer in USA (unspecified route)